NF-κB c-Rel 是急性角膜移植拒绝的潜在治疗标
Qian Zheng1,2, Ruiling Liu1, Bian Jiang3
1Eye Institute of Shandong First Medical University, State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Qingdao, China.
Investigative ophthalmology & visual science
|November 14, 2023
概括
核因子kappa B (NF-κB) c-Rel是角膜移植排斥的一个危险因素. 用AAV6-shRel或PTXF准c-Rel有效地减少排斥和炎症,没有副作用.
科学领域:
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
- 分子生物学分子生物学
背景情况:
- 急性角膜移植排斥涉及复杂的炎症途径.
- 核因子kappa B (NF-κB) 信号传递,特别是c-Rel子单元,与免疫反应有关.
- 了解c-Rel在角膜移植中的作用对于开发新的治疗策略至关重要.
研究的目的:
- 研究NF-κBc-Rel在急性角膜移植排斥中的作用.
- 评估针对c-Rel在减少角膜移植排斥的有效性.
主要方法:
- 在野生型和c-Rel缺陷小鼠中进行的异构角膜移植.
- 使用裂光灯显微镜评估移植的存活率,不透明度,新血管化和水.
- 使用表达c-Rel特异性小毛RNA (AAV6-shRel) 和氧fylline (PTXF) 的腺相关病毒6 (AAV6) 抑制c-Rel.
主要成果:
- 在角膜移植排斥中,c-Rel表达和炎症点升高.
- 在小鼠中,c-Rel的损失显著降低了角膜移植排斥.
- AAV6-shRel和PTXF治疗降低了c-Rel和炎症性细胞因子的调节,减少了没有毒性的排斥.
结论:
- 升高的c-Rel表达是急性角膜移植排斥的危险因素.
- 向c-Rel提供了一种有前途的治疗方法,以缓解角膜移植排斥.
- 在临床前模型中,c-Rel的治疗抑制证明了安全性和有效性.
相关概念视频
02:26NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
147
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
147